NP与MVP方案对复治的晚期非小细胞肺癌近期疗效  

The Short Term Effect of Vinorelbine / Cisplatin and Mitomycin / Vindesine /Cisplatin in the Treatment for Refractory Advanced NSCLC

作　　者：励佩 王韡旻[2] 杨新法[2] 张朝晖 

机构地区：[1]上海市徐家汇地段医院,上海200030 [2]上海市胸科医院,上海200030

出　　处：《中国肿瘤》2002年第8期483-484,共2页China Cancer

摘　　要：[目的]评价含顺铂的联合方案NP与MVP对复治的晚期非小细胞肺癌的近期疗效。[方法]106例晚期非小细胞肺癌随机被分为两组。NP组48例 ,其中Ⅲb期12例 ,Ⅳ期36例 ,鳞癌12例 ,腺癌30例 ,鳞腺混合型6例 ,采用诺维本25mg/m2 静脉推注 ,第1,8天 ;顺铂90mg/m2 静脉滴注 ,第1天 (配合水化 )。MVP组58例 ,其中Ⅲb期8例 ,Ⅳ期50例 ,鳞癌14例 ,腺癌36例 ,鳞腺混合型8例 ,采用丝裂霉素6mg/m2 静脉推注 ,第1天 ;VDS3mg/m2 静脉推注 ,第1,8天 ;顺铂90mg/m2 ,静脉滴注 ,第1天 (配合水化 )。两方案均为每3周为1周期 ,治疗2周期后评价疗效与毒副反应。[结果]NP组有效率(RR)为37.5% ,MVP组RR为31.0% ,差异无显著性 (P>0.05)。腺癌疗效比鳞癌稍好 ,主要毒副反应为骨髓抑制、消化道反应、周围神经毒性及静脉炎。目前均能采取相应的防治措施。[结论]NP与MVP方案均为治疗非小细胞肺癌的第一线治疗方案 ,也适用于复治的晚期非小细胞肺癌 。To evaluate the short term effect of cisplatin_based combined chemotherapy NP regimen and MVP regimen for non_small cell lung cancer(NSCLC). One hundred and six cases of advanced NSCLC were treated with either vinorelbine/cisplatin (NP) (n=48) or mitomycin/vindesine/cisplatin (MVP) (n=58) regimen. In NP Group 12 cases were phase Ⅲb and 36 cases are phase Ⅳ. There were 12 cases of squamous carcinoma and 30 of adenocarcinoma and 6 of mixed type(NVB 25mg/m2 iv day 1,8; cisplatin 90mg/m2 iv infusion day 1). In MVP group 8 cases were phase Ⅲb and 50 cases are phase Ⅳ. There were 14 cases of squamous carcinoma and 36 of adenocarcinoma and 8 of mixed type(MMC 6mg/m2 iv day 1; VDS 3mg/m2 iv day1,8; cisplatin 90mg/m2 iv infusion day 1). The two regimens were given every three weeks as one cycle.Effect and toxicity were evaluated after two cycles. The response rates of NP and MVP were 37.5% and 32.1%, respectively. There were no significant difference between the two regimens (P>0.05). The response rate in adenocarcinoma was higher than that in squamous carcinoma. The main side effects were myelosppression, GI and peripheral nerve toxicity and phlebitis.[Conclusion] NP and MVP regimens maybe as the first line chemotherapy regimens for NSCLC,and also applied in the treatment of refractory advanced NSCLC and community hospitals.

关 键 词：非小细胞肺癌 药物疗法 顺铂 诺维本 长春地辛 NSCLC 

分 类 号：R734.2[医药卫生—肿瘤]